Eli Lilly and Company (LLY)vsSS Innovations International Inc. Common Stock (SSII)
LLY
Eli Lilly and Company
$934.60
+9.80%
HEALTHCARE · Cap: $760.43B
SSII
SS Innovations International Inc. Common Stock
$4.02
-4.06%
HEALTHCARE · Cap: $838.55M
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 153318% more annual revenue ($65.18B vs $42.48M). LLY leads profitability with a 31.7% profit margin vs -28.5%. LLY earns a higher WallStSmart Score of 78/100 (B+).
LLY
Strong Buy78
out of 100
Grade: B+
SSII
Avoid22
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LLY.
Margin of Safety
+86.5%
Fair Value
$24.60
Current Price
$4.02
$20.58 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 101 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 44.9%
Revenue surging 42.6% year-over-year
Earnings expanding 51.4% YoY
Revenue surging 79.1% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 31.5x book value
0.0% earnings growth
Smaller company, higher risk/reward
Trading at 20.1x book value
ROE of -46.9% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.7% and operating margin at 44.9%. Revenue growth of 42.6% demonstrates continued momentum.
Bull Case : SSII
The strongest argument for SSII centers on Revenue Growth. Revenue growth of 79.1% demonstrates continued momentum.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.60 is elevated, increasing financial risk.
Bear Case : SSII
The primary concerns for SSII are EPS Growth, Market Cap, Price/Book.
Key Dynamics to Monitor
LLY profiles as a growth stock while SSII is a hypergrowth play — different risk/reward profiles.
SSII carries more volatility with a beta of 1.91 — expect wider price swings.
SSII is growing revenue faster at 79.1% — sustainability is the question.
LLY generates stronger free cash flow (678M), providing more financial flexibility.
Bottom Line
LLY scores higher overall (78/100 vs 22/100), backed by strong 31.7% margins and 42.6% revenue growth. SSII offers better value entry with a 86.5% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →SS Innovations International Inc. Common Stock
HEALTHCARE · MEDICAL DEVICES · USA
SS Innovations International, Inc., is a commercial-stage surgical robotics company in India and internationally. The company is headquartered in Gurugram, India.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?